InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,523.20
(
0.59%
)
Dow Jones
38,834.86
(
0.00%
)
Brent Oil
84.74
(
0.05%
)
Bitcoin
66,130.00
(
1.79%
)
Post# of 252256
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: oc631 post# 153126

Thursday, 11/29/2012 12:16:08 AM

Thursday, November 29, 2012 12:16:08 AM

Post# of 252256
RE:IL28B



The irrelevance of IL28B status is a fine example of the changes in the oral HCV space.

Considering the disparity between results we are seeing in GT2 and GT3 patients I feel it would be prudent for the FDA to require the genotypes to be tested separately. The grouping of GT2 and GT3 under oral therapy is now becoming a dated clinical practice of prior interferon-based treatment.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up